Turning Point Therapeutics, Inc. (TPTX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Turning Point Therapeutics, Inc. (TPTX) Healthcare & Pipeline Overview

Turning Point Therapeutics, Inc. is a clinical-stage precision oncology biopharmaceutical company focused on developing tyrosine kinase inhibitors (TKIs) for genetically driven cancers. Its pipeline targets ROS1+, NTRK+, MET, RET, and ALK alterations in both TKI-naïve and pretreated patients, aiming to address unmet medical needs in advanced solid tumors.

What Is the Investment Thesis for TPTX?

Turning Point Therapeutics, Inc. presents a focused investment thesis centered on its advanced clinical-stage pipeline of precision oncology tyrosine kinase inhibitors (TKIs). The company's strategy targets specific genetic drivers of cancer, addressing patient populations with high unmet needs in both TKI-naïve and TKI-pretreated settings. Key value drivers include the ongoing Phase 1/2 TRIDENT-1 trial for repotrectinib in ROS1+ NSCLC and NTRK+ solid tumors, alongside other promising candidates like TPX-0022 (MET/SRC/CSF1R inhibitor), TPX-0046 (RET inhibitor), and TPX-0131 (ALK inhibitor), all progressing through early-phase clinical studies. While the company exhibits a Profit Margin of -767.3%, typical for a clinical-stage biotechnology firm investing heavily in R&D, its Gross Margin of 100.0% reflects the nature of its intellectual property-driven business model prior to commercialization. The acquisition by Bristol-Myers Squibb Company on August 15, 2022, provides significant financial and operational resources, potentially accelerating pipeline development, regulatory pathways, and eventual commercialization efforts. The successful advancement and potential approval of its lead candidates represent substantial growth catalysts, positioning the company to capture market share in targeted oncology.

Based on FMP financials and quantitative analysis

TPTX Key Highlights

• Profit Margin of -767.3%, indicative of a clinical-stage biotechnology company's significant R&D investment prior to product commercialization.
• Gross Margin of 100.0%, reflecting the company's focus on intellectual property development and lack of significant cost of goods sold in its clinical phase.
• Beta of -0.19, suggesting a low correlation with broader market movements, which can be characteristic of companies whose value is tied to specific clinical milestones.
• Operates with 267 employees, a focused team size for a specialized clinical-stage biopharmaceutical company.
• Became a subsidiary of Bristol-Myers Squibb Company on August 15, 2022, integrating its pipeline and expertise within a major pharmaceutical entity.

Who Are TPTX's Competitors?

TPTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TPTX's Key Strengths?

• Specialized pipeline of novel tyrosine kinase inhibitors (TKIs) targeting specific genetic alterations in cancer.
• Lead candidate repotrectinib in advanced Phase 1/2 trials for ROS1+ NSCLC and NTRK+ solid tumors.
• Strategic acquisition by Bristol-Myers Squibb provides substantial financial, R&D, and commercialization resources.
• Focus on TKI-naïve and TKI-pretreated patients addresses significant unmet medical needs.

What Are TPTX's Weaknesses?

• Clinical-stage company with no commercialized products, leading to negative profit margins.
• High dependence on the successful outcome of ongoing and future clinical trials.
• Pipeline is concentrated in oncology, making the company susceptible to market shifts or regulatory changes in this specific therapeutic area.
• As a subsidiary, strategic decisions and resource allocation are now dictated by Bristol-Myers Squibb.

What Could Drive TPTX Stock Higher?

• Continued progress and data readouts from the Phase 1/2 TRIDENT-1 trial for repotrectinib in ROS1+ advanced NSCLC and NTRK+ advanced solid tumors, which could support future regulatory submissions.
• Advancement of TPX-0022 through the Phase 1 SHIELD-1 clinical trial for MET-altered advanced solid tumors, with upcoming data potentially informing further development stages.
• Progression of TPX-0046 in the 1/2 SWORD-1 clinical trial for RET genetic alterations, with ongoing patient enrollment and data generation.
• Development of TPX-0131 in the Phase 1/2 FORGE-1 study for TKI-pretreated ALK-positive NSCLC, aiming to address resistance mechanisms in this patient population.
• Potential for new clinical trial initiations or expansion cohorts for existing pipeline candidates, broadening their therapeutic scope or target patient populations.

What Are the Key Risks for TPTX?

• Negative return on equity (-22.9%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures, where drug candidates may not meet primary or secondary endpoints for efficacy or safety, leading to termination of development programs.
• Regulatory hurdles, including delays in obtaining necessary approvals from health authorities or outright rejection of marketing applications for pipeline drugs.
• Intense competition within the precision oncology space, with numerous companies developing similar or superior targeted therapies, potentially limiting market share.
• Intellectual property challenges, including patent disputes or the inability to secure adequate patent protection for novel compounds, which could undermine market exclusivity.
• Integration risks as a subsidiary of Bristol-Myers Squibb, including potential shifts in strategic priorities or resource allocation that could impact the pace or direction of pipeline development.

What Are the Growth Opportunities for TPTX?

• Growth opportunity 1: Advancement and potential approval of repotrectinib for ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. The ROS1+ NSCLC market, though a smaller segment, represents a significant unmet need, especially for TKI-pretreated patients. Successful completion of the TRIDENT-1 trial and subsequent regulatory approvals could unlock a substantial revenue stream, potentially reaching hundreds of millions in annual sales for these indications, with a timeline dependent on trial outcomes and regulatory review, likely within the next 3-5 years. The precision targeting offers a competitive edge against less specific therapies.
• Growth opportunity 2: Development and commercialization of TPX-0022, a MET/SRC/CSF1R inhibitor, for advanced solid tumors with MET genetic alterations. MET alterations are found in various cancers, including NSCLC, gastric, and renal cell carcinoma, representing a diverse patient population. The ongoing Phase 1 SHIELD-1 trial aims to demonstrate efficacy and safety. The market for MET inhibitors is growing, with several competitors, but TPX-0022's specific inhibition profile could offer differentiation. Successful clinical progression could lead to market entry within a 5-7 year timeframe, addressing a multi-billion dollar market segment.
• Growth opportunity 3: Progression of TPX-0046, a RET inhibitor, through clinical trials for advanced solid tumors with RET genetic alterations. RET fusions and mutations are oncogenic drivers in a subset of NSCLC, thyroid cancer, and other solid tumors. The 1/2 SWORD-1 clinical trial is crucial for establishing its profile. The RET inhibitor market is emerging, with new approvals establishing benchmarks. A differentiated RET inhibitor could capture a significant share of this market, which is estimated to be in the hundreds of millions to low billions, depending on indications, within a 4-6 year horizon.
• Growth opportunity 4: Successful development of TPX-0131, an ALK inhibitor, for advanced or metastatic TKI-pretreated ALK-positive NSCLC. ALK-positive NSCLC is a well-established indication with existing TKI treatments, but resistance often develops. TPX-0131 aims to address this TKI-pretreated population, offering a potential next-generation solution. The Phase 1/2 FORGE-1 study is critical for demonstrating its efficacy in this challenging setting. Capturing even a fraction of the relapsed/refractory ALK+ NSCLC market, which is a significant segment of the broader NSCLC market, could represent a substantial opportunity within 5-7 years.
• Growth opportunity 5: Leveraging the resources and infrastructure of Bristol-Myers Squibb (BMS) following the acquisition. As a subsidiary, Turning Point Therapeutics benefits from BMS's extensive R&D capabilities, global commercialization network, and financial strength. This integration can accelerate clinical development timelines, enhance manufacturing capabilities, and streamline regulatory processes, potentially bringing its pipeline therapies to market more efficiently and broadly than as an independent entity. This strategic alignment provides a long-term growth catalyst, enhancing the probability of success for its entire pipeline over the next decade.

What Opportunities Does TPTX Have?

• Potential for repotrectinib to become a best-in-class TKI for ROS1+ and NTRK+ cancers, capturing significant market share.
• Expansion of pipeline indications for existing drug candidates or development of new targeted therapies.
• Leveraging Bristol-Myers Squibb's global reach and established commercial infrastructure for accelerated market entry upon approval.
• Addressing resistance mechanisms in TKI-pretreated patients, a growing area of need in oncology.

What Threats Does TPTX Face?

• Clinical trial failures or unexpected safety concerns could halt development and diminish pipeline value.
• Intense competition from other pharmaceutical and biotechnology companies developing similar targeted oncology therapies.
• Regulatory hurdles and delays in obtaining marketing approvals from health authorities like the FDA and EMA.
• Patent expiry or challenges to intellectual property could impact future revenue streams.
• Evolving treatment paradigms or discovery of superior therapies could render current candidates less competitive.

What Are TPTX's Competitive Advantages?

• Proprietary pipeline of novel tyrosine kinase inhibitors (TKIs) designed to overcome resistance mechanisms.
• Focus on specific, well-defined genetic drivers of cancer, allowing for targeted development and potentially higher efficacy.
• Intellectual property protection through patents on its drug candidates and their use.
• Expertise in precision oncology and drug discovery, particularly in TKI development.
• Strategic backing and resources from parent company Bristol-Myers Squibb, providing a significant competitive advantage in terms of funding, R&D infrastructure, and market access.

What Does TPTX Do?

Turning Point Therapeutics, Inc., founded in 2013 and headquartered in San Diego, California, is a clinical-stage precision oncology biopharmaceutical company dedicated to designing and developing innovative therapies that specifically target genetic drivers of cancer. The company's strategic focus is on creating a robust pipeline of novel tyrosine kinase inhibitors (TKIs) engineered to address the challenges of TKI-naïve and TKI-pretreated patients, thereby offering potential solutions for difficult-to-treat cancers. Its lead drug candidate, repotrectinib, is a central component of its development efforts, currently undergoing evaluation in the ongoing Phase 1/2 TRIDENT-1 trial. This trial targets patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and those with ROS1+ and NTRK+ advanced solid tumors, representing patient populations with significant unmet medical needs. Beyond repotrectinib, Turning Point Therapeutics maintains a diversified pipeline. This includes TPX-0022, a MET/SRC/CSF1R inhibitor, which is in the Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET. Additionally, TPX-0046, a RET inhibitor, is progressing through the 1/2 SWORD-1 clinical trial for patients with advanced solid tumors characterized by RET genetic alterations. The company's portfolio also features TPX-0131, an ALK inhibitor, which is being investigated in the Phase 1/2 FORGE-1 study for patients with advanced or metastatic TKI-pretreated ALK-positive NSCLC. This comprehensive approach underscores Turning Point Therapeutics' commitment to developing targeted therapies that can improve outcomes for cancer patients. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company, integrating its precision oncology expertise within a larger pharmaceutical framework.

What Products and Services Does TPTX Offer?

• Designs and develops precision oncology therapies targeting genetic drivers of cancer.
• Focuses on tyrosine kinase inhibitors (TKIs) for both TKI-naïve and TKI-pretreated patients.
• Develops repotrectinib for ROS1+ advanced non-small-cell lung cancer (NSCLC) and ROS1+/NTRK+ advanced solid tumors.
• Investigates TPX-0022, a MET/SRC/CSF1R inhibitor, for advanced solid tumors with MET genetic alterations.
• Advances TPX-0046, a RET inhibitor, for advanced solid tumors harboring RET genetic alterations.
• Develops TPX-0131, an ALK inhibitor, for advanced or metastatic TKI-pretreated ALK-positive NSCLC.
• Conducts multiple Phase 1/2 clinical trials for its lead drug candidates.
• Operates as a subsidiary of Bristol-Myers Squibb Company since August 2022.

How Does TPTX Make Money?

• Primarily a research and development-driven entity, focused on advancing drug candidates through clinical trials.
• Generates value through the development of novel intellectual property in precision oncology.
• Prior to acquisition, its business model would have relied on securing funding through equity financing, partnerships, or eventual product sales.
• As a subsidiary of Bristol-Myers Squibb, its value generation is now integrated into the parent company's broader portfolio and strategic objectives.
• Potential future revenue streams, if products are commercialized, would come from sales of its approved oncology therapies.

What Industry Does TPTX Operate In?

Turning Point Therapeutics, Inc. operates within the highly specialized and rapidly evolving biotechnology industry, specifically focusing on precision oncology. This segment is characterized by the development of targeted therapies that address specific genetic mutations or biomarkers in cancer patients, moving away from traditional broad-spectrum chemotherapy. The broader oncology market is projected to continue its robust growth, driven by advancements in genomic sequencing, increasing prevalence of cancer, and a strong pipeline of innovative drugs. Turning Point Therapeutics' emphasis on tyrosine kinase inhibitors (TKIs) for targets like ROS1, NTRK, MET, RET, and ALK positions it within a competitive yet high-potential niche. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms also developing targeted oncology agents. Companies like Mirati Therapeutics, Inc. (MRTX) are direct competitors in the targeted oncology space, while Alpine Immune Sciences, Inc. (ALPN) and Opthea Limited (OPT) represent broader biotechnology peers. The company's strategy aligns with the industry trend towards personalized medicine, aiming to deliver more effective treatments with reduced side effects by precisely targeting cancer's molecular drivers.

Who Are TPTX's Key Customers?

• Target patient populations suffering from specific genetically driven cancers, such as ROS1+ NSCLC, NTRK+ solid tumors, MET-altered tumors, RET-altered tumors, and ALK-positive NSCLC.
• Oncologists and specialized healthcare providers who prescribe targeted cancer therapies.
• Global healthcare systems and payers who approve and reimburse for novel oncology treatments.
• As a subsidiary, its internal 'customers' also include Bristol-Myers Squibb's R&D and commercialization teams.

Company Profile

Turning Point Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Athena Maria Countouriotis. TPTX has traded publicly since 2019.

How Turning Point Therapeutics, Inc. Is Valued

Relative to its peer group, TPTX's quantitative score of 63/100 is roughly in line with the peer average of 70/100.

ROE -23%Key Financial Metrics

Return on equity for Turning Point Therapeutics, Inc. stands at -22.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.6%, showing how much profit it generates from its asset base. A current ratio of 21.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.7%, the inverse of the P/E and a quick read on earnings relative to price.

TPTX Financials

TPTX Latest News

No recent news available for TPTX.

TPTX Analyst Consensus

TPTX MoonshotScore

Common Questions About TPTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources